Stock News

Keryx Biopharmaceuticals (KERX) Holding Lifted by Abrams Capital Management Lp; As Baidu (BIDU) Share Value Declined, River & Mercantile Asset Management Llp Has Boosted Its Stake

Baidu, Inc. (NASDAQ:BIDU) Logo

River & Mercantile Asset Management Llp increased its stake in Baidu Inc (BIDU) by 35.87% based on its latest 2017Q4 regulatory filing with the SEC. River & Mercantile Asset Management Llp bought 95,159 shares as the company’s stock declined 3.38% with the market. The institutional investor held 360,430 shares of the technology company at the end of 2017Q4, valued at $84.38M, up from 265,271 at the end of the previous reported quarter. River & Mercantile Asset Management Llp who had been investing in Baidu Inc for a number of months, seems to be bullish on the $81.53B market cap company. The stock increased 1.86% or $4.27 during the last trading session, reaching $234.17. About 1.06 million shares traded. Baidu, Inc. (NASDAQ:BIDU) has risen 36.72% since April 17, 2017 and is uptrending. It has outperformed by 25.17% the S&P500.

David Abrams increased its stake in Keryx Biopharmaceuticals Inc (KERX) by 69.94% based on its latest 2017Q4 regulatory filing with the SEC. Abrams Capital Management Lp bought 4.00M shares as the company’s stock declined 10.62% with the market. The hedge fund run by David Abrams held 9.72 million shares of the health care company at the end of 2017Q4, valued at $45.19 million, up from 5.72M at the end of the previous reported quarter. Abrams Capital Management Lp who had been investing in Keryx Biopharmaceuticals Inc for a number of months, seems to be bullish on the $560.72M market cap company. The stock increased 3.41% or $0.155 during the last trading session, reaching $4.705. About 199,966 shares traded. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has declined 32.44% since April 17, 2017 and is downtrending. It has underperformed by 43.99% the S&P500.

Among 24 analysts covering Baidu (NASDAQ:BIDU), 10 have Buy rating, 3 Sell and 11 Hold. Therefore 42% are positive. Baidu had 65 analyst reports since July 28, 2015 according to SRatingsIntel. Macquarie Research downgraded the stock to “Neutral” rating in Monday, October 31 report. The stock of Baidu, Inc. (NASDAQ:BIDU) has “Underperform” rating given on Wednesday, October 7 by Daiwa Securities. Jefferies maintained Baidu, Inc. (NASDAQ:BIDU) rating on Thursday, May 12. Jefferies has “Buy” rating and $203 target. The firm earned “Hold” rating on Tuesday, July 28 by Brean Capital. The company was maintained on Monday, June 19 by Jefferies. On Wednesday, August 31 the stock rating was initiated by JP Morgan with “Underweight”. Brean Capital upgraded Baidu, Inc. (NASDAQ:BIDU) on Friday, April 29 to “Buy” rating. Macquarie Research upgraded Baidu, Inc. (NASDAQ:BIDU) rating on Friday, July 28. Macquarie Research has “Buy” rating and $25200 target. The company was initiated on Monday, December 19 by Cantor Fitzgerald. The firm earned “Equal-Weight” rating on Monday, October 30 by Barclays Capital.

River & Mercantile Asset Management Llp, which manages about $4.01B and $892.31M US Long portfolio, decreased its stake in Priceline Group Inc/The (NASDAQ:PCLN) by 300 shares to 1,796 shares, valued at $3.12M in 2017Q4, according to the filing. It also reduced its holding in Ferrari Nv by 20,288 shares in the quarter, leaving it with 800 shares, and cut its stake in Vanguard S&P Small (VIOO).

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals had 37 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) earned “Buy” rating by TH Capital on Monday, August 10. On Friday, February 26 the stock rating was downgraded by JP Morgan to “Neutral”. TH Capital maintained the stock with “Buy” rating in Thursday, July 23 report. The firm earned “Buy” rating on Tuesday, August 2 by Ladenburg Thalmann. Morgan Stanley maintained the stock with “Equal-Weight” rating in Thursday, February 8 report. The stock has “Equal-Weight” rating by Morgan Stanley on Monday, October 5. The stock of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) earned “Hold” rating by Cowen & Co on Friday, June 16. As per Monday, August 10, the company rating was downgraded by Roth Capital. Maxim Group maintained the stock with “Buy” rating in Thursday, July 27 report. As per Friday, February 26, the company rating was maintained by Stifel Nicolaus.

Abrams Capital Management Lp, which manages about $7.62B and $2.97B US Long portfolio, decreased its stake in Wells Fargo Co New (NYSE:WFC) by 478,681 shares to 2.86 million shares, valued at $173.74M in 2017Q4, according to the filing.

Investors sentiment decreased to 1.02 in Q4 2017. Its down 0.48, from 1.5 in 2017Q3. It dived, as 20 investors sold KERX shares while 32 reduced holdings. 20 funds opened positions while 33 raised stakes. 74.81 million shares or 1.05% less from 75.60 million shares in 2017Q3 were reported. Baldwin Brothers Ma owns 43,000 shares. Manitoba – Canada-based Great West Life Assurance Can has invested 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Jpmorgan Chase accumulated 21,769 shares or 0% of the stock. Parametric Port Associate Ltd Liability Company has 325,386 shares. State Common Retirement Fund invested in 89,500 shares. Architects owns 282 shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 7,574 shares. Cornerstone Capital Management Llc owns 41,500 shares for 0% of their portfolio. Tower Rech Cap (Trc) holds 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 623 shares. Clearbridge Investments Lc owns 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 4,269 shares. Fmr Lc reported 1.69M shares. Citigroup holds 1,525 shares or 0% of its portfolio. Northern Trust Corp has invested 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Voya Ltd invested in 38,137 shares. Goldman Sachs invested in 689,423 shares.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *